Hoth Therapeutics Files 8-K

TL;DR

HOTH filed an 8-K on Jan 24 for Jan 23 events, mostly other events and financials.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on January 24, 2025, reporting on events that occurred on January 23, 2025. The filing primarily concerns other events and includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in New York.

Why It Matters

This 8-K filing indicates that Hoth Therapeutics, Inc. is providing updates on its corporate activities and financial reporting to the SEC.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on corporate events and financial statements, not indicating any immediate significant operational or financial distress.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• January 23, 2025 (date) — Date of earliest event reported
• January 24, 2025 (date) — Date of Report
• Nevada (jurisdiction) — State of incorporation
• New York (location) — Address of principal executive offices

FAQ

From the Filing

0001213900-25-006526.txt : 20250124 0001213900-25-006526.hdr.sgml : 20250124 20250124161532 ACCESSION NUMBER: 0001213900-25-006526 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250123 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250124 DATE AS OF CHANGE: 20250124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 25554400 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0228609-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-01-23 2025-01-23 0001711786 dei:FormerAddressMember 2025-01-23 2025-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) January 23, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 5066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   590 Madison Ave. , 21 st Floor New York , New York 10022 (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events.   On January 23, 2025, Hoth Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market, LLC (“Nasdaq”) stating that because the Company’s common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company had regained compl